Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Another important question concerns the mechanism by which a
2025-02-07

Another important question concerns the mechanism by which a polyubiquitinated substrate is released from the Cdc48 complex and passed on to downstream components, such as the proteasome. There are at least three proposed models. In the first, a ubiquitinated substrate is transferred by ubiquitin-bi
-
Aurora B is also known as chromosomal passenger protein
2025-02-07

Aurora-B is also known as chromosomal passenger protein and localizes at the chromosome arms and at centromeres during prophase. As cell cycle continues, Aurora-B moves towards the inner centromere region followed by the central spindle and cortex during ALW-II-41-27 and finally accumulates in the
-
Neuropathic animals display increased sensitivity
2025-02-07

Neuropathic animals display increased sensitivity to the anti-nociceptive effect of baclofen and whilst the number and affinity of GABAB Coelenterazine BRET assays in the dorsal horn are not altered (Smith et al., 1994; Zemoura et al., 2016), GABAB receptors subunits (B1 and B2) are both down-regul
-
br Conclusion br Acknowledgements br Introduction Synapses a
2025-02-07

Conclusion Acknowledgements Introduction Synapses are the fundamental elements of neuronal networks that enable the processing, encoding, and retrieval of information in the brain, and pathological disruptions in synapse structure are broadly held to underlie the development of neurological
-
The use of FTAI can overcome
2025-02-07

The use of FTAI can overcome the negative impact of low estrus detection efficiency, but implies effective synchrony of luteal function as well as synchronous growth and ovulation of a viable Avermectin derivative follicle. Pregnancy rates obtained with FTAI may be comparable or better than those o
-
Arginases from several species and
2025-02-07

Arginases from several species and tissues have been found to be inhibited by amino acids [51]. In the present study, monocarboxyilic amino acids with five or more carbon atoms such as ornithine, lysine, valine, leucine and isoleucine inhibited CL-ARG. The results revealed that as the amino p2y rece
-
The activity of MMPs is regulated at the
2025-02-07

The activity of MMPs is regulated at the level of gene transcription or by the enzymatic activation of latent enzymes. Inflammatory cytokines such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α and IL-6 are elevated in synovial fluid, synovium and cartilage in patients with OA, and these cyto
-
Not all secondary metabolites or natural products can
2025-02-07

Not all secondary metabolites or natural products can be fully synthesized due to their very complex structures that are too difficult and expensive on industrial scale. Hence, there is an urgent need to search for alternative remedies as naturally occurring biologically active secondary metabolites
-
br Alzheimer s disease AD
2025-02-07

Alzheimer’s disease (AD) is an irreversible, age-associated neurodegenerative disorder that is characterized by progressive memory loss and cognitive decline. AD is also the leading cause of dementia, accounting for 5 million cases in the United States and 44 million cases worldwide. In 2015, AD c
-
Clinical observations of individuals with a decrease in LOX
2025-02-07

Clinical observations of individuals with a decrease in 12-LOX 61603 are consistent with 12-LOX potentiating platelet activation and thrombus formation [40]. However, the relative contribution of 12-LOX to these complex disorders cannot be fully elucidated in the absence of a biochemical assessment
-
For patients who have taken
2025-02-07

For patients who have taken advantage of the anti-TKIs and whose follow-up has been succeeded, some partial response has been noticed with 45% (9/20) for gefitinib, 39% (9/23) for erlotinib and 56.5% (13/23) for crizotinib. A disease progression has also been observed with 35% (7/20) for gefitinib,
-
Although the immobilization by histidine tag exhibits effect
2025-02-06

Although the immobilization by histidine tag exhibits effectiveness in oriented enzyme immobilization, it still faces some challenges [31]. On one hand, some unnecessary metal-binding proteins that interfere with the combination between the target protein and the supports or the additional interacti
-
The results also showed that the A receptor http www
2025-02-06

The results also showed that the A3 receptor agonist increased the phosphorylated levels of Akt, leading to activation of the PI3K/Akt pathway. A3 Asunaprevir stimulation has protective effects against RGC death following ischemia-reperfusion, glutamate toxicity, and optic nerve transection models
-
Materials and methods br Results br Discussion The
2025-02-06

Materials and methods Results Discussion The BV-tag-based electrochemiluminescence immunoassay is an extremely sensitive assay. It has been employed for detecting analytes present in only picogram quantities (e.g., bacterial toxins [26], bml definition [19]), measuring the activity of basic
-
Several reports of single cases of MG patients treated with
2025-02-06

Several reports of single cases of MG patients treated with Rituximab have claimed a favourable response (Baek et al., 2007, Gajra et al., 2004, Hain et al., 2006, Thakre et al., 2007, Wylam et al., 2003, Zaja et al., 2000). We report our experience with Rituximab in 6 patients with severe MG, 3 pa
15936 records 26/1063 page Previous Next First page 上5页 2627282930 下5页 Last page